Menu
Previous
Next
Previous
Next

ABRAXANE

Abraxane is the tradename for the drug agent known as Nab-paclitaxel which was derived from the drug paclitaxel (sold as Taxol). Paclitaxel is one of the taxane family of drugs and is approved for the treatment of a number of cancers including, those of the breast, lung, and other solid tumors. Nab-paclitaxel is a formulation of paclitaxel that is attached to albumin which alters the metabolism, efficacy and side-effects profile of the underlying agent.

Paclitaxel was discovered in 1962 by a U.S. NCI (funded) drug screening effort, and was later assiduously harvested from the bark of Taxus brevifolia, The Pacific (or western) yew tree, a confer located in the Pacific Northwest area of the U.S. and Canada. Since the mid to late 90s, it has been manufactured synthetically.

The mechanism of action of Paclitaxel is the inhibition of microtubules necessary for mitosis and thus slowing or stopping cell growth.

Abraxane was developed by the biotech firm Calgene. On September 6, 2013, Abraxane in combination with gemcitabine was approved by the U.S. Food and Drug Administration for the treatment of metastatic pancreatic cancer.

We have commented on the use of Abraxane in the treatment pancreatic cancer in the Pancreatica Blog: Here and Here.

Our Philosophy About Pancreatic Cancer

Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco

WHY US? BECAUSE EARLY DIAGNOSIS IS KEY

Currently, only about 15% of those diagnosed with pancreatic cancer are eligible for potentially curative surgery. We need to find the disease earlier!

Pancreatic cancer is very aggressive. Fortunately together, so are we.

We are dedicated to promoting awareness, increasing education, and furthering pancreatic cancer research.

Cancer Patients Alliance is a 501(c)(3) non-profit. Initiatives include, ToFightCancer.com and Pancreatica.org. All Donations are tax-deductible. Pancreatic cancer is the least funded cancer in terms of research.

Despite causing enormous mortality, pancreatic cancer receives (on a mortality basis) much less funding for research than most of the other major cancers. Currently, there is no molecular marker or genetic screening tool to aid in the earlier diagnosis or screening of pancreatic cancer. Treatment results would improve significantly if this cancer could be diagnosed at an earlier stage.

Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to help fight pancreatic cancer!
AmazonSmile is the same Amazon you know. Same products, same prices, same service. Simply use our Link to start shopping!

WAYS TO MAKE AN IMPACT.

Walk, Run, or Choose your own!

Choose a walk, run, or any other activity that you like and work to raise donations leading up to your Event! Simply set up your participation page and we will be in touch!

DEDICATE YOUR RACE

Already registered for your next Race? Dedicate your participation to Pancreatic Cancer. Simply set up your participation page and together we will work towards our shared mission!

ON FACEBOOK​

Creating a Facebook Fundraiser is easy: Click the Link below and Facebook will take you through the steps! Dedicate your Birthday or another important date to honor a loved one.

Join us on Social Media !

Pancreatic cancer is the most aggressive of the major cancers, has the highest mortality rate, and is the LEAST funded.
CLICK HERE TO MAKE A TAX-DEDUCTIBLE DONATION !

 

Call us at: 831-372-0900 or Email: participate@tofightcancer.com

Our mission is to promote awareness, increase education, and further pancreatic cancer research, specifically research aimed at early diagnosis.

Studies show that death rates for pancreatic cancer are increasing while for most other cancers they are declining, we need change !

Early diagnosis is key:
Survival increases dramatically if patients are diagnosed in time for surgery!

For medical information Click Here for our sister site Pancreatica.org

Pancreatica.org is a top-rated internet resource containing unique educational resources for patients, their caregivers, physicians and researchers, that displays an impressive concentration of scientific articles. 

Currently, no standard marker exists to diagnose the disease in early stages. Our aim is to support the development of a marker for early diagnosis. If the disease is found even a year earlier, outcomes will begin to improve.  LEARN MORE

WHY US? BECAUSE EARLY DIAGNOSIS IS KEY

Currently, only about 15% of those diagnosed with pancreatic cancer are eligible for potentially curative surgery. We need to find the disease earlier!

Pancreatic cancer is very aggressive. Fortunately together, so are we.

We are dedicated to promoting awareness, increasing education, and furthering pancreatic cancer research.

MAKE AN IMPACT

Pancreatic cancer is expected to become the 2nd leading cause of cancer-related death by the year 2020

Make a tax-deductible Donation

TOGETHER WE CAN MAKE A DIFFERENCE !